大剂量甲氨蝶呤的药代动力学监测。高危患者的早期识别。 - Suppr

Suppr

超能文献

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.

作者信息

Evans W E, Pratt C B, Taylor R H, Barker L F, Crom W R

出版信息

Cancer Chemother Pharmacol. 1979;3(3):161-6. doi: 10.1007/BF00262416.

DOI:10.1007/BF00262416

PMID:316744

Abstract

摘要

相似文献

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients.大剂量甲氨蝶呤的药代动力学监测。高危患者的早期识别。

Cancer Chemother Pharmacol. 1979;3(3):161-6. doi: 10.1007/BF00262416.

"Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.

Cancer Treat Rep. 1978 Feb;62(2):233-5.

Progress report on high-dose methotrexate (NSC-740) with citrovorum rescue in the treatment of metastatic bone tumors.大剂量甲氨蝶呤（NSC-740）联合亚叶酸钙解救治疗转移性骨肿瘤的进展报告

Cancer Chemother Rep. 1974 Mar-Apr;58(2):275-80.

High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.大剂量甲氨蝶呤联合亚叶酸钙解救及阿霉素治疗儿童骨肉瘤

Cancer. 1974 Apr;33(4):1151-63. doi: 10.1002/1097-0142(197404)33:4<1151::aid-cncr2820330439>3.0.co;2-8.

High-dose methotrexate in osteogenic sarcoma: a 5-year experience.高剂量甲氨蝶呤治疗骨肉瘤：5年经验

Cancer Treat Rep. 1978 Feb;62(2):259-64.

Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.间歇性大剂量甲氨蝶呤-“亚叶酸钙解救”治疗儿童恶性肿瘤的临床试验及药代动力学

Cancer Res. 1974 Dec;34(12):3326-31.

[Management of the administration of leucovorin calcium in high-dose methotrexate therapy].

Arzneimittelforschung. 1989 Jun;39(6):728-31.

Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy.转移性骨肉瘤对大剂量甲氨蝶呤冲击治疗联合亚叶酸钙解救及放射治疗的良好反应。

Cancer. 1973 Jun;31(6):1367-73. doi: 10.1002/1097-0142(197306)31:6<1367::aid-cncr2820310611>3.0.co;2-6.

The role of high-dose methotrexate with citrovorum factor "rescue" in the treatment of osteogenic sarcoma.大剂量甲氨蝶呤联合亚叶酸钙“解救”在骨肉瘤治疗中的作用

Int J Radiat Oncol Biol Phys. 1977 Mar-Apr;2(3-4):261-6. doi: 10.1016/0360-3016(77)90083-9.

Methotrexate revisited.

Med Pediatr Oncol. 1976;2(3):227-41. doi: 10.1002/mpo.2950020303.

引用本文的文献

Accidental methotrexate overdose leading to multisystem toxicity: A case report.甲氨蝶呤意外过量导致多系统毒性：一例报告。

Toxicol Rep. 2024 Nov 19;13:101821. doi: 10.1016/j.toxrep.2024.101821. eCollection 2024 Dec.

Low serum level and chronic toxicity for methotrexate. Case Report.甲氨蝶呤血清水平低与慢性毒性。病例报告。

Qatar Med J. 2023 Nov 13;2023(4):31. doi: 10.5339/qmj.2023.31. eCollection 2023.

Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients.采用群体药代动力学方法评价大样本癌症患者中甲氨蝶呤高剂量给药时体表面积校正剂量。

BMC Cancer. 2021 Jun 20;21(1):719. doi: 10.1186/s12885-021-08443-x.

Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.左乙拉西坦与大剂量甲氨蝶呤在淋巴瘤患者中无药物相互作用。

Pharmacotherapy. 2021 May;41(5):430-439. doi: 10.1002/phar.2516. Epub 2021 Mar 16.

High-dose methotrexate in ICU patients: a retrospective study.重症监护病房患者使用大剂量甲氨蝶呤：一项回顾性研究。

Ann Intensive Care. 2020 Jun 13;10(1):81. doi: 10.1186/s13613-020-00693-5.

Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma.肥胖原发性中枢神经系统淋巴瘤患者大剂量甲氨蝶呤清除率的体尺寸、形态计量学和肾功能比较。

Pharmacotherapy. 2020 Apr;40(4):308-319. doi: 10.1002/phar.2379. Epub 2020 Mar 27.

Pharmacokinetic basis for dosing high-dose methotrexate in infants and young children with malignant brain tumours.婴幼儿恶性脑肿瘤大剂量甲氨蝶呤给药的药代动力学基础。

Br J Clin Pharmacol. 2020 Feb;86(2):362-371. doi: 10.1111/bcp.14160. Epub 2020 Jan 8.

Identifying risk factors for high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia.识别急性淋巴细胞白血病患儿中高剂量甲氨蝶呤诱导毒性的危险因素。

Cancer Manag Res. 2019 Jul 5;11:6265-6274. doi: 10.2147/CMAR.S207959. eCollection 2019.

Preventing and Managing Toxicities of High-Dose Methotrexate.预防和管理大剂量甲氨蝶呤的毒性反应

Oncologist. 2016 Dec;21(12):1471-1482. doi: 10.1634/theoncologist.2015-0164. Epub 2016 Aug 5.

Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma.叶酸代谢途径基因多态性对小儿骨肉瘤大剂量甲氨蝶呤治疗后毒性的影响。

Blood Res. 2016 Mar;51(1):50-7. doi: 10.5045/br.2016.51.1.50. Epub 2016 Mar 25.

本文引用的文献

Methotrexate tissue distribution: prediction by a mathematical model.甲氨蝶呤的组织分布：通过数学模型进行预测

J Natl Cancer Inst. 1971 Apr;46(4):775-84.

Methotrexate pharmacokinetics.甲氨蝶呤的药代动力学。

J Pharm Sci. 1971 Aug;60(8):1128-33. doi: 10.1002/jps.2600600803.

Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern.

Eur J Cancer (1965). 1972 Aug;8(4):409-14. doi: 10.1016/0014-2964(72)90125-9.

Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma.甲氨蝶呤对携带Lewis肺癌的小鼠多个组织的相对毒性。

J Pharmacol Exp Ther. 1974 Jun;189(3):585-92.

Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues.甲氨蝶呤在体内抑制正常和肿瘤靶组织中DNA合成的阈值浓度。

J Clin Invest. 1973 Aug;52(8):1804-11. doi: 10.1172/JCI107362.

Cancer Res. 1974 Dec;34(12):3326-31.

Effective absorption and utilization of oral formyltetrahydrofolate in man.人体对口服甲酰四氢叶酸的有效吸收与利用

N Engl J Med. 1972 Jan 27;286(4):175-9. doi: 10.1056/NEJM197201272860402.

Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.中等剂量和高剂量甲氨蝶呤（NSC - 740）在人体中的处置与代谢动力学模型。

Cancer Chemother Rep. 1975 Jul-Aug;59(4):811-7.

The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides.亚叶酸钙和核苷对甲氨蝶呤对小鼠骨髓细胞细胞毒性的逆转作用。

Cancer Res. 1976 Dec;36(12):4418-24.

High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity.实体瘤的大剂量甲氨蝶呤治疗：与临床毒性相关的观察结果

Med Pediatr Oncol. 1976;2(3):319-25. doi: 10.1002/mpo.2950020313.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验